Monday, July 23, 2012 (Last Updated: 07/25/2012)
Marla J. Keller, M.D., from the Albert Einstein College of Medicine in Bronx, N.Y., and colleagues examined the five-year cumulative incidence of cervical precancer or cancer, defined cytologically or histologically, in 420 HIV-infected and 279 HIV-uninfected women with a normal Papanicolaou test result at baseline who were negative for oncogenic HPV.
The researchers found that 88 percent of HIV-infected women and 91 percent of HIV-uninfected women with normal cervical cytology had no oncogenic HPV detected. During five years of follow-up there were two cases of high-grade squamous intraepithelial lesions or greater among these HPV-negative women (one in an HIV-uninfected women and one in an HIV-infected women with a CD4 count of 500 cells/µmL or greater). Based on histologic data from four sites, there were six cases of cervical intraepithelial neoplasia (CIN)-2 or greater in 145 HIV-uninfected women and nine cases in 219 HIV-infected women, for a cumulative incidence of 5 percent in both groups of women. CIN-3 was noted in one HIV-infected and one HIV-uninfected woman, but none had cancer.
"The current investigation highlights the potential for a new era of molecular testing, including HPV as well as other biomarkers, to improve cervical cancer screening in HIV-infected women," the authors write.
Several authors disclosed financial ties to the pharmaceutical and medical device industries.
Hematology & Oncology
Copyright © 2012 HealthDay. All rights reserved.